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Background: Depressive symptoms are a common problem in patients with diabetes, laying an additional burden
on both the patients and the health care system. Patients suffering from these symptoms rarely receive adequate
evidence-based psychological help as part of routine clinical care. Offering brief evidence-based treatments aimed
at alleviating depressive symptoms could improve patients’ medical and psychological outcomes. However,
well-designed trials focusing on the effectiveness of psychological treatments for depressive symptoms in patients
with diabetes are scarce. The Mood Enhancement Therapy Intervention Study (METIS) tests the effectiveness of two
treatment protocols in patients with diabetes. Individually administered Cognitive Behavioral Therapy (CBT) and
Mindfulness-Based Cognitive Therapy (MBCT) are compared with a waiting list control condition in terms of their
effectiveness in reducing the severity of depressive symptoms. Furthermore, we explore several potential
moderators and mediators of change underlying treatment effectiveness, as well as the role of common factors and
treatment integrity.
Methods/design: The METIS trial has a randomized controlled design with three arms, comparing CBT and MBCT
with a waiting list control condition. Intervention groups receive treatment immediately; the waiting list control
group receives treatment three months later. Both treatments are individually delivered in 8 sessions of 45 to
60 minutes by trained therapists. Primary outcome is severity of depressive symptoms. Anxiety, well-being,
diabetes-related distress, HbA1c levels, and intersession changes in mood are assessed as secondary outcomes.
Assessments are held at pre-treatment, several time points during treatment, at post-treatment, and at 3-months
and 9-months follow-up. The study has been approved by a medical ethical committee.
Discussion: Both CBT and MBCT are expected to help improve depressive symptoms in patients with diabetes. If
MBCT is at least equally effective as CBT, MBCT can be established as an alternative approach to CBT for treating
depressive symptoms in patients with diabetes. By analyzing moderators and mediators of change, more
information can be gathered for whom and why CBT and MBCT are effective.
Trial registration: Clinical Trials NCT01630512.
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Depression is a common comorbidity of diabetes, nega-
tively affecting adherence to medication, dietary and
exercise recommendations, and patients’ medical outcomes
(Ciechanowski et al., 2000; Ciechanowski et al., 2003).
Psychological therapies can be considered as the treatment
of choice for depression in somatic patient popula-
tions, as they do not interfere with medical treatment
regimes, have no physical side-effects, and are often
preferred by patients in comparison to antidepressant drugs
(Dwight-Johnson et al., 2000; Lustman & Clouse 2002).
Additionally, one of the important advantages of a psy-
chological approach over a pharmacological approach
to treat depression is that psychological therapies provide
patients with tools which enable them to cope with future
symptoms of depression, and thereby may reduce the risk
of relapse of this highly recurrent disorder. Although there
is evidence from systematic reviews and meta-analyses for
the efficacy of psychological treatment for depression in pa-
tients with diabetes in general (Baumeister et al., 2012; van
der Feltz-Cornelis et al., 2010), little is known about which
specific types of psychological intervention are effective.
The most commonly used and recommended type of
psychotherapeutic intervention for depression is Cognitive
Behavioral Therapy (CBT), a short-term intervention
focusing on behavioral activation and changing negative
thoughts. In a recent meta-analysis on the effectiveness
of CBT for depression in patients with a diversity of
somatic diseases (including diabetes), CBT was found to
significantly reduce depressive symptoms compared to
control conditions (Beltman et al., 2010). Specifically in
patients with diabetes, only four randomized controlled
trials have been conducted so far to test the effectiveness
of CBT in treating depression. All four RCTs have found
that CBT is effective in reducing depressive symptoms
(Lamers et al., 2010; Lustman et al., 1998; Penckofer et al.,
2012; van Bastelaar et al., 2011).
In the past decades, another type of cognitive therapy,
namely Mindfulness-Based Cognitive Therapy (MBCT)
has become increasingly popular, both in clinical practice
and research. MBCT integrates CBT with mindfulness. The
concept mindfulness has been defined as “paying attention
in a particular way: on purpose, in the present moment,
and nonjudgmentally” (Kabat-Zinn 2003). Mindfulness-
based interventions involve practicing this form of
attentiveness, or awareness, both in formal exercises
(like meditation and yoga) and in informal exercises in
daily life.
CBT and MBCT both encourage awareness of thoughts
and feelings and to adequately regulate them, yet they dif-
fer in how to learn to adjust to such experiences. In CBT
the main components are behavioral activation and critic-
ally challenging and replacing the content of negative
thoughts, while the main component in MBCT is to learnto relate differently to thoughts and feelings, in a nonjudg-
mental and accepting way, merely observing them as they
come and go. MBCT has been designed as a method to
prevent recurrence of depression in patients with prior
history of depressive disorder (Segal et al., 2002), yet,
there is increasing evidence that MBCT is also effect-
ive in the treatment of current depressive symptoms
(Hofmann et al., 2010). Among patients with diabetes,
only five studies (two observational trials and three
randomized controlled trials) have been conducted so far
testing the effectiveness of mindfulness-based interventions,
showing decreases in psychological distress (Hartmann
et al., 2012; Rosenzweig et al., 2007; Schroevers et al.,
2013; van Son et al., 2013; Young et al., 2009). A recent
randomized controlled trial investigating the effect of
MBCT for patients with diabetes found a greater re-
duction of depressive symptoms in the mindfulness
group compared to the waiting list control condition
(van Son et al., 2013). Taken the positive effects of MBCT
into account, it is now strongly advocated to use a more
rigorous design to test its effects, namely by including not
only a control group (such as treatment-as-usual or waiting
list control), but also an active evidence-based treatment
condition, like CBT (Hofmann et al., 2010). To date only a
few small trials have directly compared CBT and MBCT as
two active treatments (Manicavasagar et al., 2012; Zautra
et al., 2008). None of them have been conducted in a
diabetic population with depressive symptoms.
Current study
The present Mood Enhancement Therapy Intervention
Study (METIS) aims to study the effectiveness of CBT and
MBCT in relation to a control condition. Taking into
account the limited number of RCTs and thus limited
empirical evidence for the effectiveness of CBT and MBCT
for depressive symptoms in patients with diabetes, we
believe that it is important to compare both interventions
to a control condition. By examining both CBT and MBCT
in one trial, our research not only enables the study of their
differential effectiveness but it also provides the opportunity
to clarify the mechanisms whereby CBT and MBCT are
efficacious and to identify for whom each treatment is likely
to be most beneficial. Therefore, we explore the role of sev-
eral mediators, moderators, common factors, and treatment
integrity in treatment outcomes, which will be described in
more detail in the following part.
Our primary interest is the examination of effects of CBT
and MBCT on depressive symptoms in patients with dia-
betes. In order to study possible effects of a wider range of
outcomes, anxiety, well-being, diabetes-related distress, and
intersession changes in mood are assessed as secondary
outcomes. In addition to investigating secondary effects of
CBT and MBCT on these psychological outcomes, we
assess effects on the medical outcome HbA1c. Previous
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treatment also leads to an improvement in diabetes
self-management and subsequent glycemic control
(Detweiler-Bedell et al., 2008). Two recent RCTs on CBT
and MBCT for depression in patients with diabetes found
that glycemic control did not improve after psychological
treatment (van Bastelaar et al., 2011; van Son et al., 2013)
To further clarify this important topic, glycemic control as
indicated by HbA1c levels is included as an exploratory
secondary outcome.
In this study, both interventions are administered indi-
vidually in eight face-to-face sessions. Individual CBT for
depression has already proven to be effective in persons
with a somatic disease, even more than group delivery of
CBT (Beltman et al., 2010). In contrast, MBCT is usually
delivered and tested in a group setting. Such a group setting
may be supportive (Griffiths et al., 2009). However, it has
also been indicated that a large group of people prefers
individual over group delivery of MBCT (Lau et al., 2012)
and that some people participating in a group mindfulness-
based intervention found group sharing frustrating and not
beneficial (Griffiths et al., 2009). Moreover, it may not
always be possible to offer a group program, especially
in hospital settings. Group interventions require that all
patients are able to come at a common time and patients
may have to wait quite a while until a sufficient number of
group participants is available. For these reasons, we under-
took the challenge to adapt the standardized treatment
protocol of group MBCT for individual therapy. A pilot
study that investigated the feasibility and acceptability of
individual MBCT for people with diabetes and comorbid
psychological distress found that most patients were satis-
fied with the treatment and considered it as helpful. More-
over, MBCT led to reductions in depressive symptoms and
diabetes related distress (Schroevers et al., 2013).
Mediators
Only recently, research has started to examine why and
how MBCT may work in reducing psychological symp-
toms, by studying underlying mechanisms of change.
This research is still in its infancy, especially compared
to CBT for which more evidence is available regarding
its mediators of effects. Moreover, little is known about
the extent to which mechanisms of change are unique or
possibly overlapping between CBT and MBCT (Driessen
& Hollon, 2010; Shapiro et al., 2006). In order to fill
this gap and address this fundamental issue, we investigate
mediators of CBT and MBCT and make comparisons
among both treatments. Based on previous empirical
studies as well as the treatment components and theories
underlying CBT and MBCT, three groups of mediators are
selected: mediators specific for CBT (e.g., behavioral
activation and cognitive reappraisal), mediators specific
for MBCT (e.g., mindfulness and self-compassion), andmediators assumed to play a role in both treatments
(e.g., overidentification).
Moderators
Currently, there is also a lack of information regarding
factors that may moderate the effectiveness of treatment.
Such information is of clinical importance as it may indi-
cate groups of persons likely or not to benefit from treat-
ment. In order to examine for whom CBT and MBCT are
(not) effective, several moderators are examined in the
current study. First, we examine the moderating role of
baseline psychological factors, including demographic and
personality trait factors (i.e. neuroticism, attachment style)
(see Bagby et al., 2008; Cordon et al., 2009; McBride et al.,
2006) and history of depression, as the latter has been
found to play a moderating role in previous MBCT studies
(Segal et al., 2002). Second, we explore baseline medical
and biological moderating factors. We examine the in-
fluence of diabetes specific characteristics (i.e. type and
duration of diabetes, diabetes complications, and previous
hospital admissions due to severe hypoglycemia) and deg-
radation of tryptophan on treatment outcome. Tryptophan
serves as a precursor for serotonin and plays an important
role in depression (Russo et al., 2009). Functioning as a nat-
ural antidepressant, tryptophan could therefore influence
treatment outcome (Thomson, 1982).
Common factors
Common factors that are shared by different treatment
modalities such as the therapeutic alliance and patients’
treatment expectancies, have been shown to predict
positive change in psychotherapy (Martin et al., 2000;
Noble et al., 2001). Yet, the role of these factors on treat-
ment outcome has hardly been studied in MBCT. We
therefore study the associations between the alliance, ex-
pectancies and subsequent change in depressive symp-
toms among the two treatment conditions.
Treatment integrity
It has been firmly recommended to measure treatment
integrity in randomized controlled trials to be able to draw
valid conclusions on the treatment effects (e.g. Moncher &
Prinz, 1991; Perepletchikova et al., 2007). Treatment integ-
rity refers to whether the intervention was implemented
as intended (Kazdin & Nock, 2003). Two aspects of
treatment integrity are investigated: the extent to which
therapists adhere to procedures described in the proto-
col (treatment adherence) and whether CBT and MBCT
differ in the intended manner (treatment differentiation)
(Waltz et al., 1993).
Homework assignments are a central component of
CBT and MBCT. Research has shown that compliance
to homework assignments positively predicts treatment
outcome in CBT (Kazantzis et al., 2000). Furthermore,
Tovote et al. BMC Psychology 2013, 1:17 Page 4 of 10
http://www.biomedcentral.com/2050-7283/1/17homework compliance may explain the associations
between common factors and depressive symptom change
(e.g. Westra et al., 2007). In the present study, we examine
patients’ compliance to homework as well.
Study aim and hypotheses
The primary objective of this study is to assess immediate
and long-term effects of CBT and MBCT in reducing
depressive symptoms in patients with diabetes. We
hypothesize that both active treatments are more effective
than a waiting list control condition in reducing depressive
symptoms. We do not expect CBT or MBCT to be super-
ior over the other. Secondary objectives are to examine po-
tential factors that mediate and moderate treatment effects
of MBCT and CBT, as an effort to gain more clarity on
why and for whom CBT and MBCT are (not) effective.
In addition, we aim to investigate the associations between




The present study is a multi-center, randomized controlled
trial (RCT). Participants are assigned to MBCT, CBT,
or a waiting list control condition. Patients allocated to
the control group are randomized for the second time and
receive one of the two treatments three months later.
The choice for a waiting list as a control condition is
based on ethical reasons, as patients are screened and all
had elevated levels of depressive symptoms. This is also
the reason why we chose a waiting period of no longer than
three months. Treatment effects are monitored over a
period of one year from baseline. This study is conducted
in accordance with the principles of the Declaration of
Helsinki (version 2008) and the Medical Research Involving
Human Subjects Act (WMO) and is approved by the
Medical Ethical Committee of the University Medical
Center Groningen (UMCG).
Recruitment and screening procedure
Figure 1 illustrates participant recruitment and flow
through the study. Patients who are currently receiving
medical treatment at one of the participating hospitals
for their diabetes are routinely screened for depressive
symptoms. They receive a letter from their diabetes out-
patient clinic with a request to fill in a questionnaire
concerning their mood (Beck Depression Inventory–II
(BDI-II) and Well-being Index (WHO-5)), either online
or in pen-and-paper version. Several hospitals, primarily
in the Northern part of the Netherlands are approached
to participate. At present, the University Medical Center
Groningen, the Martini Hospital Groningen, the Medical
Center Leeuwarden, and the Hospital Rivierenland Tiel
have agreed to take part in the study. Patients are alsoable to participate through self-referral. Patients, whose
score on depressive symptoms on the BDI-II is ≥ 14, are
invited to meet with one of the psychologists or research
assistants involved in the study. Patients who fulfill the
inclusion criteria and who give written informed consent
for participation are included in the study.
Study population
Inclusion criteria are: diagnosed with type 1 or 2 diabetes at
least three months prior to inclusion; ≥ 18 and ≤70 years of
age; having depressive symptoms as assessed by the BDI-II
score ≥ 14 (cut-off score indicating the presence of at least
mild symptoms of depression).
Exclusion criteria are: Not being able to read and write
Dutch; pregnancy; severe psychiatric comorbidity (i.e.,
recently experienced psychosis, bipolar disorder, panic
disorder, diagnosis of schizophrenia, serious cognitive
or neurological problems); acute suicidal ideations or
behavior; receiving an alternative psychological treatment
during or less than two months prior to starting the partici-
pation in the study. Using an antidepressant drug during
participation in the present study is allowed, on condition
that a patient has been on stable medication regimen for at
least two months prior to inclusion in the study, and that
no new treatment with an antidepressant is initiated during
the course of the study.
Treatment allocation
Computerized randomization within each hospital is
carried out, with participants being stratified by gender,
use of antidepressant medication, and their score on the
BDI-II at baseline.
Blinding
Prior to their randomization, patients are blinded to the
study condition. No specific information about study
design or the type of intervention is given, other than that
both treatments focus on learning to cope with negative
thoughts or feelings in a different way. The patients are told
that the treatment starts relatively soon after they have
given their consent, and that a possible waiting period is no
longer than three months. After randomization the patients
are given more precise information about the treatment
they are going to receive.
Interventions
For the current study, we chose to offer patients with
diabetes a generic treatment for depressive symptoms
(CBT or MBCT). Our argument for this decision is that
depressive symptoms may be related to diabetes for
some patients to some extent, but not necessarily for
all patients. By offering a generic rather than a diabetes-
specific treatment for depressive symptoms, we aim to re-
duce depressive symptoms in diabetes patients, irrespective
Figure 1 Participant recruitment and flow through the study.
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which they are related to diabetes and/or other import-
ant domains in the patients’ lives. During the treatment
(CBT or MBCT) patients could bring in diabetes-related
topics if relevant for their depressive mood. This way,
patients could use the learned CBT or MBCT strategies
for managing diabetes-related depressive symptoms.
The treatments consist of eight individual sessions, which
are scheduled weekly and last 45 to 60 minutes. Patients
receive a workbook with homework assignments and
are expected to spend about 30 minutes per day on these
assignments. Patients in the MBCT condition also receive
audio CDs with mindfulness exercises.
Both CBT and MBCT are led by trained therapists
who receive supervision. One MBCT therapist is a diabetes
nurse who is a qualified mindfulness therapist, all othertherapists have a master’s degree in clinical psychology
and most of them have experience with diabetic patients.
All therapists have experience in the delivery of the specific
treatment (CBT or MBCT) that they are giving to patients.
Before start of the study, the therapists receive an additional
three day training by an experienced, qualified MBCT or
CBT therapist who also provides supervision every three
weeks throughout the intervention and study period.
CBT
The CBT treatment protocol is based on CBT for de-
pression developed by Beck et al. (1979). The first part
of the treatment is devoted to behavioral components
of CBT, such as planning and undertaking of (pleasant or
functional) activities. The second part of the treatment
focuses on dysfunctional thinking patterns, allowing
Tovote et al. BMC Psychology 2013, 1:17 Page 6 of 10
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automatic thoughts.
MBCT
The MBCT treatment protocol is based on the protocol
as developed by Segal et al. (2002). MBCT integrates
cognitive therapy for depression with mindful meditation
and was originally developed to teach formerly depressed
patients new skills in order to help them prevent relapse.
Key themes include experiential learning and the develop-
ment of an open and acceptant mode of (negative) feelings,
thoughts, and body sensations (Segal et al., 2002). Formula-
tion of specific prevention strategies is included in a later
stage of treatment. Originally, MBCT is given as a 2.5-hour
per session group treatment. We developed a shortened
and individualized version of this protocol which has previ-
ously been tested in a pilot study in patients with diabetes
(Schroevers et al., 2013).
Outcome assessment
Table 1 presents an overview of the measures and the time
points on which they are assessed. Assessments take place
after consent to participate and before randomization (T1),
after the first treatment session (T2), after the second
treatment session (T3), after the fourth treatment session
(T4), directly after completion of treatment (T5), 3 months
after treatment (T6), and 9 months after treatment (T7).
The measurements during the course of treatment are used
to assess patients’ expectancies, the development of thera-
peutic relationship, and the process of change in mediator
and outcome variables. At T1 and T5, patients are also
interviewed and their depressive symptoms are rated by the
interviewer by means of a structured clinical interview.
The T5 interview also evaluates patients’ acceptability
and satisfaction with the received treatment, what they
learned, and what they found most or least helpful. All
treatment sessions of patients that provide consent are
videotaped. Patients are also asked consent for sampling a
maximum of 3 ml extra blood in order to assess trypto-
phan. Participants in the waiting list condition receive the
first assessment (T1) twice, first directly after given consent
and then again at the end of the 3-months waiting period.
After a second randomization, they receive the same
assessments as participants in the CBT and MBCT condi-
tion. We realize it may be a burden for patients to fill out
all these assessments. Therefore, we made careful consider-
ation which questionnaires to include. In order to enhance
patients’ commitment to the study and to reduce attrition,
all patients are assigned to a specific contact person
throughout the study period.
Primary outcome measure
The primary outcome of the study is severity of depres-
sive symptoms as assessed with the Beck DepressionInventory-II (BDI-II) (Beck et al., 1996). In addition to the
self-report depression measurement, depressive symptoms
are assessed in a semi-structured clinical interview using
the 7-Item Hamilton Depression Rating scale (HAM-D7)
(Mclntyre et al., 2005).
Secondary outcome measures
Psychological secondary outcomes are generalized anxiety
measured by the Generalized Anxiety Disorder scale
(GAD-7) (Spitzer et al., 2006), well-being measured by the
Well-being Index (WHO-5) (Bech, 2004), diabetes-related
distress measured by the Problem Areas in Diabetes scale
(PAID) (Polonsky et al., 1995), and intersession changes
in mood assessed by the Emotion Thermometers Tool
(ETT) (Mitchell et al., 2010). Medical secondary outcome
is glycemic control as indicated with HbA1c values, which
are retrieved from patients’ records. We access the standard
measurements of the outpatient clinics and use the average
of values half a year before intervention as pre-treatment
measure and the values half a year after intervention as
post-treatment measure.
Moderating factors
The NEO- Five Factor Inventory (NEO-FFI) (McCrae &
Costa, 2004) and the Experiences in Close Relationship
Scale short form (ECR-S) (Wei et al., 2007) are included
as measures of neuroticism and attachment style re-
spectively. History of depression is assessed by the use
of the Structured Clinical Interview for DSM-IV (SCID-I)
(First et al., 2002). Demographic and diabetes specific
characteristics are retrieved from patients’ medical records
and patients’ blood samples are used to investigate degrad-
ation of tryptophan.
Mediating factors
Cognitive coping is measured by two subscales of the
Cognitive Emotion Regulation Questionnaire (CERQ),
namely positive re-interpretation and positive refocus-
ing (Garnefski & Kraaij, 2007) and by two subscales
of the Thought Control Questionnaire (TCQ), namely
reappraisal and distraction (Wells & Davies, 1994).
Furthermore, to measure behavioral activation we use
the Behavioral Activation for Depression Scale (BADS)
(Kanter et al., 2007) and to measure rumination we
use the Rumination-Reflection Questionnaire (RRQ)
(Trapnell & Campbell, 1999). Mindfulness is assessed
with two subscales of the Five Facet Mindfulness
Questionnaire (FFMQ), namely non-judgmental atti-
tude and act with awareness (Baer et al., 2006). At-
tention control is assessed with the Self-Regulation
Scale (Brown et al., 1999). Self-compassion is measured
using three subscales of the Self Compassion Scale (SCS),
namely self-kindness, self-judgment, and overidentification
(Neff, 2003).
Table 1 Instruments to assess primary outcome, secondary outcomes, moderators, mediators, and common factors
Concept Measurement (items)** Measurement in time points*
T1 T2 T3 T4 T5 T6 T7
Primary outcome measure
Depressive symptoms BDI-II (21) x x x x x x
HAMD-7 (7) x x
Secondary outcome measures
Generalized anxiety GAD-7 (7) x x x x
Well-being WHO-5 (5) x x x x
Diabetes-related distress PAID (20) x x x x
Intersession changes in mood*** Emotion Thermometers (5)
Glycemic control (from patients’ records) HbA1c x x
Moderators
Psychological moderators
Neuroticism NEO-FFI (12) x
Attachment style ECR-S (12) x x
History of depression SCID x
Demographic characteristics - x
Biological moderators
Diabetes specific characteristics (from patients’ records) - x
Degradation of tryptophan trp/kyn x
Mediators
Cognitive coping
Positive re-interpretation and positive refocusing CERQ (8) x x x x x
Reappraisal and distraction TCQ (12) x x x x x
Behavioral activation
Behavioral activation BADS (7) x x x x x
Rumination
Rumination RRQ (12) x x x x x
Mindfulness
Non-judgmental attitude and act with awareness FFMQ (16) x x x x x
Attention control Self-Regulation Scale (10) x x x x x
Self-compassion
Self-kindness, self-judgment, and overidentification SCS (13) x x x x x
Common factors
Therapeutic alliance WAI-12 (12) & 18-item Rapport Quest. (18) x x
Patient expectancy - (3) x
* T1 baseline; T2 after first session; T3 after second session; T4 after fourth session; T5 after eighth session (post-treatment); T6 three months after training; T7 nine
months after training.
** BDI-II - Beck Depression Inventory-II; HAMD-7 - Hamilton Depression Rating Scale; Emotion Thermometers; GAD-7 - Generalized Anxiety Disorder Scale; WHO-5
Well-being Index; PAID - The Problem Areas in Diabetes scale; NEO-FFI - NEO- Five Factor Inventory; ECR-S - The experiences in close relationship scale short form;
SCID - Structured Clinical Interview for DSM-IV; CERQ - Cognitive Emotion Regulation Questionnaire; TCQ - Thought Control Questionnaire; BADS -Behavioral
Activation for Depression Scale; RRQ - Rumination-Reflection Questionnaire; FFMQ - Five Facet Mindfulness Questionnaire; Self-Regulation Scale; SCS - Self
Compassion Scale; WAI-12 - Working Alliance Inventory; 18-item Rapport Questionnaire.
*** assessed at the start of every treatment session.
Note: this table does not cover measures of treatment integrity.
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The Working Alliance Inventory (WAI-12) (Horvath &
Greenberg, 1989) and the 18-item Rapport Questionnaire(Bernieri, 2005) are selected as measures of patients’
reports of the therapeutic alliance. Patients’ expectan-
cies of improvement are assessed with a three-item
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and Nau (1972).
Treatment integrity
Videotaped treatment sessions are rated on therapists’
adherence to the treatment protocol by two independent
observers. Patients’ homework compliance is assessed
with checklists that capture the homework assignments
proscribed by the MBCT and CBT treatment protocols.
Patients are asked to complete the checklist every day of
the coming week and to return the checklist at the next
therapy session.
Sample size
The sample size calculation is based on differences in
post-treatment depressive symptoms between the waiting
list control group and one of the psychological intervention
groups. A 5 point difference on the BDI-II (assuming a
standard deviation of 8 points) between the waiting list
control group and one of the intervention groups is
considered a clinically relevant difference. In accordance
with previous research (Keers et al., 2005), a Number
Needed to Treat of 2.0 is considered cost-efficient and clin-
ical relevant. Stated differently, at least half of participants
should improve 5 points on the BDI-II. Testing two-sided,
a sample size of 42 patients per group (126 patients in total)
yields to an effect size of 0.6 according to Cohen with a
power of 80%, and an alpha of 0.05 (Cohen, 2003). This
number allows us to test the effectiveness of both in-
terventions, compared to the waiting list control, using
intention-to-treat analyses. Allowing a drop-out rate of
25%, we are able to include 32 patients in each of our
three conditions in completer analyses.
Analysis plan
Primary analyses are conducted according to the
intention-to-treat approach. To answer the primary
research question, repeated measures analyses of (co)
variance ((M)AN(C)OVA) are performed, using pri-
mary and secondary outcomes as dependent variables
and type of treatment as independent variable. If there
are significant differences between the patient popula-
tions of the different hospitals, we will perform multi-
level analyses. Baseline values of dependent variables
are included as covariate along with other baseline
measures of demographic characteristics that contribute
significantly to analysis. Clinical effectiveness is calcu-
lated with the reliable change index (RCI) (Jacobson &
Truax, 1991). Analyses for mediation and moderation
effects, common factors, and treatment integrity are
done using condition process analyses in SPSS, growth
curve analyses (structural equation modeling), and repeated
measures analyses.Discussion
Our study is the first to investigate the effectiveness of
CBT and MBCT in one randomized controlled trial in
patients with diabetes. Both interventions are expected
to improve depressive symptoms in patients diagnosed
with diabetes and suffering from comorbid symptoms of
depression, in comparison to a waitlist control group. In
case of positive findings, CBT and/or MBCT may be con-
sidered a valuable addition to standard care of patients
with diabetes and comorbid depressive symptoms. For
ethical reasons, we include a waiting list control condition
(rather than treatment-as-usual, TAU) as all participants
have elevated levels of depressive symptoms at start of the
study. Consequently, we cannot examine long-term effects
of CBT and MBCT compared to control condition.
The primary outcome of this study is severity of depres-
sive symptoms, yet we also examine possible effects on
several other psychological outcomes as well as on patients’
medical outcome, specifically on values of HbA1c. In order
to burden the patients as little as possible, the values are
obtained from their medical records instead of scheduling
additional measurements at designated time points. A
limitation to this approach is that the values are rather
general and that we cannot compare CBT and MBCT
with the control condition regarding changes in HbA1c
values. Yet, we examine pre- to post-treatment changes in
HbA1c values for all participating patients.
If MBCT proves to be effective in reducing depressive
symptoms in our study, it can be established as a sound
alternative to CBT for treating depressive symptoms in
patients with diabetes. The choice to study MBCT in an
individual therapy mode is novel and may be promising,
as not all patients are able and willing to participate in a
standard MBCT group treatment. Since both interventions
in this study are offered as a structured individualized
protocol of eight sessions, they may be especially suitable
for a medical setting where patients often receive short
individual treatments.
In addition to studying the effectiveness of the two
treatment protocols, the current study intends to examine
potential unique and joint factors which moderate and me-
diate treatment effects in CBT and MBCT, and to investi-
gate the associations between common factors, treatment
integrity, and depressive symptom improvement. Posing
such questions aims for more than just a comparison of
treatments in a most straightforward way (do they work
or not?), but rather a look under the surface (how, why,
and for which patients they might or might not work). A
strength of the current study is that we assess predictor
variables not only before and after treatment, but also dur-
ing treatment. This gives us the possibility to measure tem-
poral precedence and make inferences about causality.
By increasing the empirical evidence for the psycho-
logical treatment of depressive symptoms in people with
Tovote et al. BMC Psychology 2013, 1:17 Page 9 of 10
http://www.biomedcentral.com/2050-7283/1/17diabetes, we hope that insights into which treatment works
best for whom and how, will help improve the care of pa-
tients with diabetes who experience depressive symptoms.
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